Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Sutimlimab (Primary)
- Indications Autoimmune disorders; Autoimmune haemolytic anaemia; Bullous pemphigoid; Haematological disorders; Renal transplant rejection
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Bioverativ; True North Therapeutics
- 18 Jan 2019 Planned number of patients changed from 98 to 122.
- 18 Jan 2019 Planned End Date changed from 1 Oct 2018 to 1 Mar 2021.
- 18 Jan 2019 Planned primary completion date changed from 17 Jun 2018 to 1 Mar 2021.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History